# A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Study · id `cardio:ct-nct06897202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06897202](<https://clinicaltrials.gov/study/NCT06897202>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06897202

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

## Technical summary

Registry record NCT06897202. Randomized; double masking; primary purpose treatment. Start 2025-03-14 (actual); primary completion 2025-12-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 133 participants (enrolled count; ClinicalTrials.gov record NCT06897202, source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)
- Started: 2025-03-14 (actual) (ClinicalTrials.gov record NCT06897202, source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)
- Primary completion: 2025-12-29 (actual) (ClinicalTrials.gov record NCT06897202, source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)
- Completion: 2026-03-18 (actual) (ClinicalTrials.gov record NCT06897202, source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06897202, source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06897202-2026-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
- Acronym: VESPER-2
- Condition: Obesity in Diabetes
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): MET097 Injection
- Intervention (Drug): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: b4b82d27f2c92dc8e612998a17a45e93afd63bc338187d2575c3f0ed3622e1d9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
